Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5913-5918

  Newman, William G ^a,b   Hadfield, Kristen D ^a   Latif, Ayshe ^a   Roberts, Stephen A ^b   Shenton, Andrew ^a   McHague, Christopher ^a   Lalloo, Fiona ^a   Howell, Sacha ^c   Evans, D Gareth ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOCHROME P450 2D6; FLUOXETINE; TAMOXIFEN; THIORIDAZINE; TRAZODONE; ANTIESTROGEN;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG METABOLISM; ENZYME ACTIVITY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; SURVIVAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; ESTROGEN ANTAGONISTS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOTYPE; HUMANS; MIDDLE AGED; MUTATION; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 53249086540     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5235     Document Type: Article

References (46)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
2. Jemal A, Siegel R, Ward E, MurrayT, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
3. Miki Y Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature1995;378:789-92.
5. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003;348:2339-47.
6. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol 2007; 4:578-90.
7. Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther 2007;11:133-44.
8. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-8.
9. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 2006;84:16-28.
10. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35.
11. Pierce LJ, Levin AM, RebbeckTR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437-43.
12. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
13. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
14. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92.
15. Tamoxifen for early breast cancer: an overview of the randomized trials-Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
16. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-81.
17. Gronwald J, Tung N, Foulkes WD, et al. Hereditary Breast Cancer Clinical Study Group. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006;118:2281-4.
18. Blackhall FH, Howell S, Newman B. Pharmacogenetics in the management of breast cancer-prospects for individualised treatment. Fam Cancer 2006; 5:151-7.
19. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P 450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310: 1062-75.
20. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982;42:317-23.
21. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
22. Jin Y, Desta Z, Steams V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
23. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
24. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P 450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-21.
25. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by Taq Man real-time PCR. Hum Mutat 2003;22:476-85.
26. R Development Core Team (2007). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org.
27. Llerena A, Berecz R, de la Rubia A, Norberto MJ, Benitez J. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 2000;22:397-401.
28. Colleoni M, Gelber S, Goldhirsch A, et al. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study GroupTrial 13-93. J Clin Oncol 2006;24:1332-41.
29. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007; 25:2664-70.
30. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97: 1652-62.
31. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82.
32. Swain SM. Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clin Oncol 2001; 19:93-7S.
33. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93.
34. Rennert G, Bisland-Naggan S, Bamett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:115-23.
35. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P 450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
36. Nowell S, Sweeney C, Winters M. et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002;94:1635-40.
37. Dunning AM. Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8: 843-54.
38. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians. Africans and their descendants. Pharmacogenomics 2002;3:229-43.
39. *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008;19:1423-9.
40. Barron Tl, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007;109:832-9.
41. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years'adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
42. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727-41.
43. Breast International Group (BIG) 1-98 Collaborative Group. Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
44. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369: 1711-23.
45. Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women with advanced breast cancer. Breast Cancer ResTreat 1999;56:25-34.
46. Aebi S, Pagani O. Treatment of premenopausal women with early breast cancer: old challenges and new opportunities. Drugs 2007;67:1393-401.